Previous 10 | Next 10 |
Cancer test maker Exact Sciences ( NASDAQ: EXAS ) said Friday that two of its convertible debt holders have agreed to accept newly issued convertible senior notes due 2030 in exchange for certain 2025 notes in a privately negotiated transaction. Per the terms, the company has agreed t...
Summary Exact Sciences is shifting its focus towards achieving positive adjusted EBITDA as a way to signal a path to eliminate cash burn. The company's long-term prospects look interesting with a pipeline spread across different timelines, including a MCED test and MRD testing. Whil...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Love it or hate it, tech investing is back on the menu in 2023. As a result, Cathie Wood’s back in the limelight. Taking a back seat to the bear market last year, Wood’s Ark Invest has been subjected to muc...
Summary Exact Sciences is beginning to stem losses and is continuing to grow revenue at a reasonable clip. Despite this, GAAP profitability is still far into the future, and the 2023 guidance is mediocre. EXAS stock does not seem compelling at these levels. Thesis Desp...
Exact Sciences ( NASDAQ: EXAS ) announced on Thursday a debt exchange transaction and a private placement of convertible senior notes. Pursuant to an exchange and purchase agreement entered with a holder of certain of 0.3750% Convertible Senior Notes due 2027 and 0.3750% Convertib...
Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes PR Newswire MADISON, Wis. , Feb. 23, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and dia...
Summary Cathie Wood and her ARK Investment Management have just turned their backs on their worst year of performance since the inception of the investing firm. The market continued to systematically dissect any leftover enthusiasm in the growth and technology space, significantly hurti...
Image source: The Motley Fool. Exact Sciences (NASDAQ: EXAS) Q4 2022 Earnings Call Feb 21, 2023 , 5:00 p.m. ET Operator Continue reading For further details see: Exact Sciences (EXAS) Q4 2022 Earnings Call Transcript
Exact Sciences Corporation (EXAS) Q4 2022 Earnings Conference Call February 21, 2023 17:00 ET Company Participants Megan Jones - Investor Relations Kevin Conroy - Chairman and Chief Executive Officer Jeff Elliott - Chief Financial Officer and Chief Operating Officer ...
The following slide deck was published by Exact Sciences Corporation in conjunction with their 2022 Q4 earnings call. For further details see: Exact Sciences Corporation 2022 Q4 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Exact Sciences Corporation Company Name:
EXAS Stock Symbol:
NASDAQ Market:
Exact Sciences Corporation Website:
2024-07-11 08:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-08 08:30:00 ET To say that Exact Sciences (NASDAQ: EXAS) hasn't performed well on the stock market this year would be an understatement. Shares of the cancer-focused biotech are down by 41%. However, the healthcare company still has some fans on Wall Street. Cathie Wood ...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management w...